It should be noted that MET AMP has been described in patients with NSCLC not previously exposed to tyrosine kinase inhibitors (TKIs) (de novo MET amplification) or as a mechanism of resistance to TKIs, mainly to EGFR (acquired MET amplification). This evidence concerns the gene EGFR and non-small cell lung carcinoma.